Clinical Neurophysiology·YesterdayAssociation among white matter lesions, rsEEG rhythms, amyloid tau markers, and cognitive status in mild cognitive impairment patientsStudy in peoplePopulationsPaper
Research Square·8 OctA Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB)Preprint: trial in peopleInterventionsPaper
Neuroscience and Biobehavioral Reviews·10 SepEEG markers of cholinergic dysfunction in Lewy body diseases: A reviewReviewBiomarkersPaper
EBioMedicine·6 AugData-driven trajectories of atrophy explain clinical heterogeneity across Lewy body diseasesStudy in peoplePopulationsPaper
AAIC 2025 Abstract·24 DecMega‐Analysis of Oscillatory and Aperiodic Resting‐State EEG Alterations in Neurodegenerative DiseasesStudy in peopleBiomarkersPaper
AAIC 2025 Abstract·23 DecEffects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co‐PathologyTrial in peopleInterventionsPaper